Hope S. Rugo, MD, FASCO
2021 Giants of Cancer Care® Chair
Hope S. Rugo, MD, FASCO
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
University of California San Francisco Helen Diller Family Comprehensive Cancer Center
San Francisco, CA


Hope S. Rugo, MD, FASCO, is a medical oncologist and hematologist specializing in breast cancer research and treatment. A Professor of Medicine, Dr. Rugo joined the Breast Care Center in 1999 after a decade of experience at University of California San Francisco (UCSF) in malignant hematology and bone marrow transplantation for a variety of diseases, including breast cancer. She entered the field of breast cancer in order to incorporate novel therapies based on an understanding of the biology of cancer with excellent quality of care into the treatment of women with breast cancer.

Dr. Rugo is the Director of Breast Oncology and Clinical Trials Education at the UCSF Helen Diller Family Comprehensive Cancer Center. She is a principal investigator of multiple clinical trials focusing on combining novel targeted therapeutics with standard treatment to improve the treatment of both early and late stage breast cancer, and has published widely in this area. Her current research interests include immunotherapy and combinations of targeted agents in the treatment of breast cancer to overcome resistance. In addition, Dr. Rugo has conducted a number of studies focusing on reducing toxicity from therapy, resulting in approval of scalp cooling to reduce chemotherapy induced hair loss, and a steroid mouthwash to reduce targeted agent stomatitis. She is an investigator and the chair of the Safety Committee for the multicenter adaptively randomized phase II I-SPY2 trial, and also serves on the Novel Agents Committee. Dr. Rugo is the co-chair of the Triple Negative Working Group and an active member of the Translational Breast Cancer Research Consortium (TBCRC), and is the principal investigator
of several TBCRC trials including a multi-center immunotherapy trial funded by the Breast Cancer Research Foundation (BCRF). She is an active member of the Alliance (formerly CALGB) Breast Committee, as well as ASCO, where she serves on the Guidelines Committee and as an editor for the Education Committee.
In addition to her research, Dr. Rugo is an active clinician, and is committed to education, regularlylecturing locally, nationally, and internationally on subjects relating to the treatment of and supportive care for breast cancer. At UCSF, Dr. Rugo runs the Breast Forum, an open bimonthly evening educational session for breast cancer patients, families, and friends from throughout the bay area.

Dr. Rugo graduated from the University of Pennsylvania School of Medicine in 1983. She completed a residency in internal medicine and primary care followed by a fellowship in hematology and oncology at the University of California San Francisco. She was a post-doctoral fellow in immunology participating in laboratory research at Stanford University from 1988-1990. In 1990, Dr. Rugo joined the faculty at UCSF in the Division of Hematology and Oncology. Dr. Rugo has been recognized for her excellence in both patient care and in teaching of both medical students and training physicians. She has received several awards including the Bank of America Giannini Foundation Award and a UCSF Clinical Cancer Center Investigator Research Program intra-mural award. In 2006, she was honored for her work in Breast Cancer Research by the Friends of the Breast Care Center.
Patrick Borgen, MD
Patrick Borgen, MD
Director, Brooklyn Breast Cancer Program
Maimonides Hospital
Brooklyn, NY
Dr. Patrick I. Borgen is Chairman of Surgery at Maimonides Medical Center in Brooklyn, New York. He also heads the Breast Center at the newly built Maimonides Cancer Center. Recruited from Memorial Sloan Kettering, Dr. Borgen was Chief, Breast Service; Head, Breast Cancer Research Laboratory; and Director, Breast Cancer Disease Management Team at Memorial. He holds a faculty position at Cornell University Medical College.

Dr. Borgen earned a BS Magna Cum Laude in Biomedical Engineering at Tulane and his MD at Louisiana State University. His postdoctoral work includes an internship and a residency at Ochsner Medical Institutions in New Orleans, Louisiana (where he was Chief Resident), and a clinical research fellowship at Memorial Sloan Kettering. In addition, he received management training in the Program for Chiefs of Clinical Services at the Harvard School of Public Health.

Dr. Borgen has received numerous research grants from the National Institutes of Health, the American Cancer Society, the Army, and the National Cancer Institute. Widely published in peer-reviewed publications, Dr. Borgen is on the Editorial Board of Annals of Surgical Oncology and on the Peer Review Board of The Journal of the American Medical Association. He is Guest Editor for Surgery, Annals of Surgery, The Journal of the American College of Surgeons, Breast Diseases, Breast Diseases Quarterly, The Breast Journal, The Lancet, Archives of Surgery, and Journal of Clinical Oncology. He is Editor of 3 major textbooks on breast disease and has contributed chapters to 15 other texts. To date, he has published 200 articles in peer-reviewed journals, 141 abstracts, and 15 editorials.

Dr. Borgen has been Chairman of the American College of Surgeons Breast Cancer Trials Group and a member of the Executive Board of Directors of the American Society for the Study of Breast Disease. He is currently on the Executive Boards of the Breast Cancer Alliance, Inc., and of Tulane University, and is a member of the American Joint Committee on Cancer, Breast Task Force.
Maurie Markman, MD
Maurie Markman, MD
President, Medicine & Science
Chief Clinical Officer CTCA Health
Cancer Treatment Centers of America
Philadelphia, PA
Dr. Maurie Markman is the President of Medicine and Science and Chief Clinical Officer CTCA Health, Cancer Treatment Centers of America. For over 30 years Dr. Markman has been engaged in clinical research in the area of gynecologic malignancies, with a particular focus on new drug development and exploring novel strategies in female pelvic cancers.

Dr. Markman has been the primary author or co-author on over 1,000 published peer-reviewed manuscripts, reviews, book chapters, editorials or abstracts, and has written, edited or co-edited 23 books on various topics in the management of malignant disease.

In 2011, Dr. Markman received the American Society of Clinical Oncology (ASCO) Statesman Award, which recognizes individual members who have shown extraordinary volunteer service, dedication and commitment to ASCO, their hospital community and the patients they serve for at least 20 years.

In May, 2018, Dr. Markman was named by OncLive® to an elite group of the 2018 Giants of Cancer Care® recognition program which celebrates pioneers, innovators and leaders who have made remarkable achievements in oncology research and clinical practice. Dr. Markman was selected in recognition of his contributions in gynecologic cancers.
Daniel George, MD
Daniel J. George, MD
Professor of Medicine and Surgery
Duke University School of Medicine
Dr Daniel George is Professor of Medicine and Surgery, Divisions of Medical Oncology and Urology in the Duke University School of Medicine. He also has appointments in the Duke Clinical Research Institute and the Duke Cancer Institute where he is the Director of Genitourinary (GU) Oncology disease-based group and is co-lead of the DCI Center for Prostate and Urologic Cancers. He is an internationally recognized clinical researcher and thought leader in GU malignancies, with over 200 peer-reviewed publications. His areas of research include new drug development and biomarkers of GU cancers with an emphasis on signal transduction pathways and cancer disparities. He has led efforts defining the clinical benefit of VEGF receptor targeted therapy in renal cell carcinoma in both the metastatic and in the adjuvant setting. In addition, Dr George has championed studies evaluating the outcomes of novel hormonal agents by race in metastatic castration resistant prostate cancer.

Dr. George has led the Duke site for the Department of Defense (DOD) Prostate Cancer Clinical Trials Consortium since 2006, specializing in Phase I and II studies in prostate cancer. He is also the PI of the MaRCC and ODYSSEY registries in advanced renal cell carcinoma and Co-PI of IRONMAN, an international, multi-sponsor supported registry in advanced prostate cancer. Dr. George recently served on the ASCO Scientific Committee for non-prostate cancer (Chair 2018), the Conquer Cancer Foundation (CCF) Young Investigator Award Committee (Chair 2019-20), the AACR Clinical and Translational Cancer Research Grants Scientific Review Committee (Chair 2017-18), the renal cancer cadre leader for the Alliance GU Scientific Committee, NCI GU Steering Committee and the NCI Renal Task Force. He also serves as a senior editor for Clinical Cancer Research and Co-editor in Chief of Clinical Advances in Hematology and Oncology. He is a section editor for UroToday and serves on the OncLive Giants of Cancer Care Committee.
Alessandra Ferrajoli, MD
Alessandra Ferrajoli, MD
Professor of Medicine
Department of Leukemia
The University of Texas M.D. Anderson Cancer Center
Houston, TX
Dr Alessandra Ferrajoli is an academic hematologist/oncologist practicing in the Leukemia Department at the University of Texas, MD Anderson since 1998. Her main area of interest includes the treatment and biology of chronic lymphocytic leukemia and its variants, and treatment of elderly patients with acute and chronic leukemia. In these fields she has authored and co-authored more than two hundred publications in peer-reviewed journals. She serves on numerous journal editorial boards and participates in grant proposal study sessions for several US and European Agencies. She is a member of several professional societies such as the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), International Society of Geriatric Oncology (SIOG), the European Society for Medical Oncology (ESMO), and the European Hematology Association (EHA).
David R. Gandara, MD
David R. Gandara, MD
Professor of Medicine Emeritus
Division of Hematology/Oncology
UC Davis Comprehensive Cancer Center
Sacramento, CA
David R. Gandara, MD, Professor of Medicine Emeritus at the University of California at Davis (UC Davis) School of Medicine is the Senior Advisor to the Director, and Director of Thoracic Oncology at UC Davis Comprehensive Cancer Center (UCDCCC). He is an internationally known clinician-scientist and lung cancer thought leader. He has led many notable research projects in lung cancer, including early therapeutics trials at various phases, cooperative group trials through the Southwest Oncology Group (SWOG), and multi-institutional translational science projects. He has been selected for many awards and honors, including the lifetime Scientific Award from the International Association for the Study of Lung Cancer (IASLC). Dr. Gandara is the principal investigator for a National Cancer Institute (NCI) UG1 award to UCDCCC for Cancer Clinical Trials. He also is currently the principal investigator for UCDCCC for the Stand Up To Cancer (SU2C) dream team award in KRAS-mutated lung cancer, and served as clinical director for the joint Jackson Laboratory (JAX)-UCDCCC patient-derived xenotransplant (PDX) program in lung cancer. He is past chair of the Southwest Oncology Group (SWOG) Lung Committee, and is founding co-chair and current member of the NCI-directed Investigational Drug Steering Committee (IDSC). He has written over 700 articles, book chapters, abstracts and editorials. He is past editor-in-chief of the journal Clinical Lung Cancer. He served as president of the IASLC from 2009-2011 and served as treasurer from 2013-2017. He is a prior member of the board of directors and secretary-treasurer of the American Society for Clinical Oncology (ASCO). He consults for a number of pharmaceutical and cancer biomarker development companies.
Yelena Y. Janjigian, MD
Yelena Y. Janjigian, MD
Associate Attending Physician
Chief, Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine at Weill Cornell Medical College
New York City, NY
Yelena Y. Janjigian MD, is Associate Professor and Chief of Gastrointestinal (GI) Oncology Service in the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK). Her research career and clinical practice are focused on improving treatment outcomes for patients with GI malignancies. She is an international expert in the management of cancers of esophagus and stomach and is leading several seminal studies that will impact the standard of care for these diseases. She produced high impact publications describing the genomic basis for esophagogastric cancer pathogenesis and secured federal grants to fund future studies. Her research is focused on developing new treatments, with a special emphasis on defining the therapeutically relevant molecular characteristics of tumors in the GI tract, with 100 peer-reviewed publications to date.
Alessandra Ferrajoli, MD
Jamile M. Shammo, MD, FASCP, FACP
Professor of Medicine and Pathology
Section of Hematology and Stem Cell Transplantation
Division of Hematology/Oncology
Rush University Medical Center
Chicago, IL
Jamile M. Shammo, MD, FASCP, FACP, is Professor of medicine and Pathology, Section of Hematology and Stem Cell Transplantation, Division of Hematology/Oncology, at Rush University Medical Center in Chicago, Illinois, where she has been practicing since 2000.

In her current position, she spearheads the MDS/MPN/Bone Marrow Failure Program. As resident education faculty leader, principal investigator of clinical trials in her area of expertise, and as chair of the protocol review and monitoring committee at Rush Cancer Institute; she is heavily involved in education, research and administrative activities in the division of Hematology/Oncology.

Dr. Shammo earned her medical degree from Aleppo Medical School in Syria, after which she completed residencies in Anatomic, and clinical Pathology, as well as Internal Medicine at McGaw Medical Center of Northwestern University, in Evanston, Illinois. She then completed a 3-year fellowship in the Division of Hematology/Oncology at University of Chicago. Dr. Shammo is board certified in anatomic and clinical pathology as well as hematology. She is a fellow of both, the American Society of Clinical Pathologists and American College of Physicians. She received the Department of Medicine Excellence in Service and Teaching Award from Rush University Medical Center in 2003, was a finalist in the Department of medicine positive environment learning award in 2014 and was chosen to receive the MDS foundation ‘Nobility in Science Award” in 2019. She is also a national coordinator for the PNH registry in the US. She founded the Chicago MDS/ MPN group in 2011 to facilitate scientific exchange among academic medical centers in Chicago and has chaired multiple city-wide meetings. She has developed and chaired multiple online CME activities pertaining to MDS, MPN as well as PNH. She has designed and conducted several investigator-initiated trials in her area of expertise. She has authored, and contributed to over 100 publications; including abstracts, posters, original papers and book chapters. She served as a reviewer for several medical journals including Journal of Clinical Oncology and Blood. As an invited speaker, Dr. Shammo lectured at national and international meetings and conferences.
  • *Kenneth C. Anderson, MD
  • *Frederick R. Appelbaum, MD
  • *James O. Armitage, MD
  • *Robert C. Bast, Jr., MD
  • Monica M. Bertagnolli, MD
  • *Joseph R. Bertino, MD
  • Michael J. Birrer, MD, PhD
  • Patrick I. Borgen, MD
  • Julie Brahmer, MD
  • Lior Z. Braunstein, MD
  • *Paul A. Bunn, Jr., MD
  • Howard Burris III, MD
  • Harold J. Burstein, MD
  • John C. Byrd, MD
  • D. Ross Camidge, MD, PhD
  • David Carbone, MD, PhD
  • Anees Chagpar, MD
  • Ajai Chari, MD
  • *Lieping Chen, MD, PhD
  • Michael A. Choti, MD, MBA
  • Ezra Cohen, MD
  • Robert Coleman, MD
  • Raoul Concepcion, MD
  • Javier Cortes, MD, PhD
  • E. David Crawford, MD
  • Massimo Cristofanilli, MD, FACP
  • Guiseppe Curigliano, MD, PhD
  • *Riccardo Dalla-Favera, MD
  • *George D. Demetri, MD
  • *Vincent T. DeVita, Jr., MD
  • *Bernard J. Escudier, MD
    *Laura J. Esserman, MD, MBA
  • David M. Euhus, MD, FACS
  • Alessandra Ferrajoli, MD
  • Robert L. Ferris, MD
  • Robert A. Figlin, MD
  • *David Gandara, MD
  • *Patricia A. Ganz, MD
  • *Judy E. Garber, MD, MPH
  • Daniel J. George, MD
  • Jill Gilbert, MD
  • *Armando Giuliano, MD
  • Lori J. Goldstein, MD
  • Andre Goy, MD, MS
  • Stephan A. Grupp, MD, PhD
  • Robert Haddad, MD
  • Balazs Halmos, MD, MS
  • Omid Hamid, MD
  • Daniel A. Hamstra, MD, PhD
  • Roy S. Herbst, MD, PhD
  • Thomas Herzog, MD
  • Leora Horn, MD, MSc
  • *Gabriel Hortobagyi, MD
  • *Susan Band Horwitz, PhD
  • *Maha H. Hussain, MB, ChB
  • Yelena Y. Janjigian, MD
  • *Bruce E. Johnson, MD
  • *David H. Johnson, MD
  • *V. Craig Jordan, OBE, PhD, DSc
  • *Hagop Kantarjian, MD
  • *Philip W.  Kantoff, MD
  • Beth Y. Karlan, MD
  • Howard Kaufman, MD
  • *Michael J. Keating, MB,BS
  • Edward S. Kim, MD
  • Henry Kuerer, MD, PhD, FACS
  • *Robert Kyle, MD
  • Mario E. Lacouture, MD
  • Corey Langer, MD
  • *Michael P. Link, MD
  • Minetta C. Liu, MD
  • Sagar Lonial, MD
  • *Charles Loprinzi, MD
  • Jason J. Luke, MD
  • *Thomas J. Lynch, Jr., MD
  • Reshma Mahtani, DO
  • Eleftherios P. (Terry) Mamounas, MD
  • *Maurie Markman, MD
  • John L. Marshall, MD
  • Maria-Victora Mateos, MD, PhD
  • *Robert J. Mayer, MD
  • Tony S.K. Mok, MD
  • Bradley J. Monk, MD, FACOG, FACS
  • Monica Morrow, MD
  • Susan O'Brien, MD
  • William K. Oh, MD
  • *Joyce O'Shaughnessy, MD
  • Sumanta Kumar Pal, MD
  • Chandler Park, MD, FACP
  • *Daniel P. Petrylak, MD
  • Lori J. Pierce, MD, FASCO, FASTRO
  • Ching-Hon Pui, MD Pui, MD
  • Elizabeth A. Rafferty, MD
  • *S. Vincent Rajkumar, MD
  • *Caroline Robert, MD, PhD
  • Charles W.M. Roberts, MD, PhD
  • Gail J. Roboz, MD
  • *Saul A. Rosenberg, MD
  • *Hope S. Rugo, MD, FASCO
  • Tanios Bekaii-Saab, MD, FACP
  • Fred Saad, MD, FRCS
  • *Charles Sawyers, MD
  • Giorgio Vitto Scagliotti, MD, PhD
  • Angeles A. Secord, MD
  • Tanguy Seiwert, MD
  • Jamile M. Shammo, MD FASCP, FACP
  • George R. Simon, MD, FACP, FCCP
  • *George W. Sledge Jr, MD
  • Mark Socinski, MD
  • *Josep Tabernero, MD, PhD
  • Debu Tripathy, MD
  • Alan P. Venook, MD
  • *Nicholas J. Vogelzang, MD
  • *Jamie H. Von Roenn, MD
  • *Everett E. Vokes, MD
  • Heather Wakelee, MD
  • *Patrick Walsh, MD
  • *Jeffrey S. Weber, MD, PhD
  • Jared Weiss, MD
  • Howard J. West, MD
  • William K. Wierda, MD, PhD
  • *Eric P. Winer, MD
  • Lori J. Wirth, MD
  • *Jedd D. Wolchok, MD, PhD
  • *W. K. Alfred Yung, MD

* Giants of Cancer Care® Inductees |  Steering Committee

Program Information:
Previous Inductees:
2013 | 2014
2015 | 2016
2017 | 2018
2019 | 2020